Related Experiment Video
Updated: Jun 2, 2026
09:44
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
[Polycystic ovary syndrome--genetic considerations]
Gabriela Dumăchiţă-Gargu1, Florentina Pricop
1Universităţii de Medicină si Farmacie Gr.T. Popa Iaşi.
Summary
Polycystic Ovarian Syndrome (PCOS) affects 8% of reproductive-aged women and is a leading cause of infertility. Understanding its complex genetic and environmental factors is crucial for prevention and management.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Genetics
Context:
- Polycystic Ovarian Syndrome (PCOS) is a prevalent endocrinopathy affecting 8% of women of reproductive age.
- Historically linked to Stein-Leventhal syndrome, PCOS is recognized as a complex systemic disorder impacting reproduction.
- It is the most frequent cause of female infertility, necessitating a deeper understanding of its pathophysiology.
Purpose:
- To explore the genetic and environmental factors contributing to the polygenic nature of Polycystic Ovarian Syndrome.
- To emphasize the importance of comprehending PCOS as a long-term metabolic disorder.
- To highlight the role of genetic studies in the prophylaxis of PCOS and its associated complications.
Summary:
- PCOS is a common endocrine disorder affecting reproductive-aged women, characterized by complex etiopathogeny.
- Research suggests a polygenic basis or gene-environment interactions contribute to PCOS development.
- Understanding genetic implications is vital for preventing PCOS and managing its long-term metabolic and reproductive consequences.
Impact:
- Improved understanding of PCOS etiology can lead to targeted prevention strategies.
- Advances in comprehending PCOS pathophysiology may enhance infertility treatments.
- Early identification of genetic predispositions can facilitate proactive health management for women at risk.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:07Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:18Polygenic Traits
When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...